Group 1 - Addex Therapeutics Ltd. Sponsored ADR (ADXN) has returned 86.9% year-to-date, significantly outperforming the average return of 10.1% for the Medical sector [2][3] - The Zacks Consensus Estimate for ADXN's full-year earnings has increased by 97% over the past 90 days, indicating stronger analyst sentiment and an improving earnings outlook [2] - Addex Therapeutics is ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [1][2] Group 2 - Addex Therapeutics is part of the Medical - Drugs industry, which consists of 180 companies and currently ranks 99 in the Zacks Industry Rank, with the industry having lost about 2.3% year-to-date [3] - Boston Scientific (BSX), another outperforming Medical stock, has returned 40.8% year-to-date and belongs to the Medical - Products industry, which has moved up by 12.5% this year [2][3] - The Medical sector overall is ranked 4 in the Zacks Sector Rank, which evaluates the strength of individual sector groups [1]

Company Performance - Hain Celestial Group, Inc. reported fourth quarter adjusted earnings per share of 13 cents, exceeding the analyst consensus estimate of 8 cents, while quarterly revenues of $418.80 million fell short of the expected $421.2 million [2] - Ensysce Biosciences, Inc. shares surged 43% to $0.6190 after receiving a $14 million multi-year grant from the NIH for the development of its PF614-MPAR opioid [2] - Addex Therapeutics Ltd saw a 39% increase in shares to $10.40 following the selection of clinical candidates from its collaboration with Indivior, with potential earnings of up to $330 million [2] - VOXX International Corporation shares rose 70% to $4.8450 after announcing a strategic alternatives process to maximize valuation [2] Company Declines - Altisource Asset Management Corporation shares plummeted 48% to $1.2250 after announcing plans to voluntarily delist from the NYSE American LLC [3] - COSCIENS Biopharma Inc. shares fell 26% to $4.3350 following results from its Phase 3 DETECT-trial [3] - American Woodmark Corporation shares decreased by 10% to $89.93 after reporting worse-than-expected first-quarter results and projecting a decline in FY25 sales [3] Commodities - Oil prices decreased by 1.8% to $76.02, while gold prices fell by 0.2% to $2,550.90 [4] - Silver prices dropped by 0.1% to $29.97, whereas copper prices increased by 0.6% to $4.3085 [4] European Market Insights - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.17% and Germany's DAX rising 0.40% [5] - The German economy contracted by 0.1% quarter-over-quarter in Q2, following a 0.2% growth in Q1 [5] - The GfK Consumer Climate Indicator for Germany fell to -22.0 in September from a revised -18.6 in the previous period [5] Asian Market Insights - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 0.47% and Hong Kong's Hang Seng Index rising 0.43% [6] - Hong Kong's trade deficit narrowed to $21.8 billion in July from a $30 billion gap in the same month last year, as exports increased more than imports [6]

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Sympos ...

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] - GABAB receptors are important in the cough neural circuit, and targeting them with allosteric modulators may offer advantages over traditional treatments like baclofen [2] Company Overview - Addex's lead drug candidate, ADX71149, is a positive allosteric modulator developed in collaboration with Janssen Pharmaceuticals and has completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is being evaluated for dyskinesia associated with Parkinson's disease and post-stroke recovery [3] - Addex is advancing a GABAB PAM program for chronic cough and has a partnership with Indivior for multiple drug candidates targeting substance use disorder [3] Research and Development - The upcoming presentation will focus on the antitussive activity of a novel GABAB receptor positive allosteric modulator in preclinical models [1] - GABAB receptor activation has been clinically validated with baclofen, but its use is limited due to side effects and tolerance issues [2] - Allosteric modulators are expected to provide higher selectivity and better tolerability compared to orthosteric compounds [2]

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The company will present findings on a novel GABAB receptor positive allosteric modulator for chronic cough at the Thirteenth London International Cough Symposium [1] Group 1: Company Overview - Addex Therapeutics is developing a portfolio of allosteric modulators targeting neurological disorders, with lead drug candidate ADX71149 having completed several Phase 2 clinical studies [3] - The second clinical program, dipraglurant, is under evaluation for dyskinesia associated with Parkinson's disease and post-stroke/TBI recovery [3] - Addex has a partnership with Indivior for GABAB PAM programs, advancing multiple drug candidates for substance use disorder and an independent program for chronic cough [3] Group 2: GABAB Receptor and Chronic Cough - GABAB receptors are expressed in airways and the cough neural circuit, and their activation has been clinically validated with baclofen, a selective GABAB agonist [2] - Baclofen's use is limited due to side effects and loss of efficacy, while targeting an allosteric binding site of the GABAB receptor is expected to offer advantages like higher selectivity and better tolerability [2]

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM). The votes represented 33.79% of the company's outstanding capital. Addex shareholders approved the 2023 annual report, the 2023 annual ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q1 2024 Earnings Conference Call June 6, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Leonildo Delgado - Baader Helvea Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics First Quarter 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, the ...

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. "Building on the recent Neurosterix transaction, which extended our cas ...

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. “Building on the recent Neurosterix transaction, which extende ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1.   Approval of the Annual Report, the Annual Fi ...